4,5-二氯-2-甲基咪唑 | 15965-33-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 4,5-二氯-2-甲基咪唑
• 中文别名: 4,5中沌/-2甭圲哺喪
• 英文名称: 4,5-dichloro-2-methyl-1H-imidazole
• 英文别名: 4,5-dichloro-2-methylimidazole；2-methyl-4,5-dichloroimidazole；4,5-dichloro-2-methyl-1H-imidazole；4,5-dichloro-2-methyl-imidazole；4.5-dichloro-2-methylimidazole
• CAS: 15965-33-0
• 化学式: C₄H₄Cl₂N₂
• mdl: MFCD00051639
• 分子量: 150.995
• InChiKey: ZWRYWVBALYOSPQ-UHFFFAOYSA-N

物化性质

• 熔点：
  246-248°C
• 稳定性/保质期：
  常温常压下稳定，避免与氧化物接触。

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 安全说明：
  S26,S36
• 危险类别码：
  R36/37/38
• 海关编码：
  2933290090
• 危险性防范说明：
  P302+P352,P337+P313,P304+P340,P312,P280,P332+P313
• 危险性描述：
  H315,H319,H335
• 储存条件：
  常温下应密闭、避光保存，并保持通风和干燥。

SDS

Name:	4 5-Dichloro-2-methyl-1h-imidazole Material Safety Data Sheet
Synonym:
CAS:	15965-33-0

Section 1 - Chemical Product MSDS Name:4 5-Dichloro-2-methyl-1h-imidazole Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
15965-33-0	4,5-Dichloro-2-methyl-1h-imidazole	97+%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation.
Ingestion:
May cause irritation of the digestive tract.
Inhalation:
Causes respiratory tract irritation.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 15965-33-0: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Off White
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 245 - 248.5 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C4H4Cl2N2
Molecular Weight: 151

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, strong acids, strong bases, reducing agents, acid chlorides.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, carbon dioxide.
Hazardous Polymerization: Not available.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 15965-33-0 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4,5-Dichloro-2-methyl-1h-imidazole - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 22 Do not breathe dust.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 15965-33-0: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 15965-33-0 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 15965-33-0 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4,5-二氯-2-甲基咪唑 、 氯乙酰胺 在 sodium hydride 作用下， 以 vaseline 、 N,N-二甲基甲酰胺 为溶剂， 反应 0.75h， 以80%的产率得到4,5-dichloro-1-carbamoylmethyl-2-methylimidazole
  参考文献：
  名称：

  新的 1-烷基-、1-苄基-和 1-芳氧基乙基取代的 4,5-二氯咪唑的合成及其抗微生物、杀原生生物和抑制真菌的特性

  摘要：

  使用烷基、苄基或芳氧基乙基卤化物从 4,5-二氯咪唑或 2-甲基-4,5- 二氯咪唑合成了以前未知的二氯咪唑的 1-烷基-、1-苄基-和 1-芳氧基乙基衍生物及其结构转变的产物。这些 N 取代的化合物对某些革兰氏阳性和革兰氏阴性细菌（金黄色葡萄球菌和大肠杆菌）具有弱抗菌活性。同时，一些获得的化合物显示出显着的对 Colpoda steinii 的杀原生生物活性，其强度可以超过临床使用的兽药 Baycox 的活性。此外，这些化合物显示出明显的抑真菌作用。

  DOI：

  10.1134/s1068162016040129

文献信息

• [EN] SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS<br/>[FR] INHIBITEURS DE BMI-1 À BASE DE PYRIDINE ET DE PYRAZINE SUBSTITUÉES
  申请人：PTC THERAPEUTICS INC

  公开号：WO2015076800A1

  公开（公告）日：2015-05-28

  Amine substituted pyridine and pyrazine compounds and forms thereof that inhibit the function and reduce the level of B -cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.

  本文描述了替代吡啶和吡嗪化合物及其形式，这些化合物抑制B-细胞特异性Moloney小鼠白血病病毒整合位点1（Bmi-1）蛋白的功能并降低其水平的方法，以及它们的用途方法，用于抑制Bmi-1的功能并降低Bmi-1的水平，以治疗由Bmi-1介导的癌症。
• Methods for preparation of 2-(4-(4-(4,5-dichloro-2-methylimidazol-1-yl)butyl)-1-piperazinyl)-5-fluoropyrimidine and salts thereof
  申请人：Laboratories del Dr. Esteve S.A.

  公开号：US06346620B1

  公开（公告）日：2002-02-12

  Methods for preparing 2-(4-(4-(4,5-dichloro-2-methylimidazol-1yl)butyl)-1-piperazinyl)-5-fluoropyrimidine and its physiologically acceptable salts are disclosed.

  公开了制备2-(4-(4-(4,5-二氯-2-甲基咪唑-1-基)丁基)-1-哌嗪基)-5-氟吡咯嘧啶及其生理上可接受的盐的方法。
• Atom‐Economic, Regiodivergent, and Stereoselective Coupling of Imidazole Derivatives with Terminal Allenes
  作者：Kun Xu、Niels Thieme、Bernhard Breit

  DOI：10.1002/anie.201309126

  日期：2014.2.17

  Pd‐catalyzed regiodivergent and stereoselective intermolecular coupling reactions of imidazole derivatives with mono‐substituted allenes are herein reported. Using a RhI/Josiphos system, perfect regioselectivities and high enantiomeric excess were obtained, while a PdII/dppf system gave linear products with high regioselectivities and high E/Z selectivities. This method permits the atom economic synthesis

  本文报道了新的Rh和Pd催化的咪唑衍生物与单取代的Allenes的区域发散和立体选择性分子间偶联反应。使用Rh I / Josiphos系统，可以获得完美的区域选择性和高对映体过量，而Pd II / dppf系统则可提供具有高区域选择性和高E / Z选择性的线性产物。该方法允许原子经济地合成有价值的支链和线性烯丙基咪唑衍生物。
• Synthesis and Structure-Activity Relationships of a New Series of Benzimidazoles as H1-Antihistaminic Agents.
  作者：Maria Rosa CUBERES、Montserrat CONTIJOCH、Carme CALVET、Julia ALEGRE、Jordi Ramon QUINTANA、Jordi FRIGOLA

  DOI：10.1248/cpb.45.1287

  日期：——

  New 2-(4-(4-azolybutyl)piperazinyl)-, 2-(4-(4-azolybutyl)piperazinylmethyl)-, 2-(4-(4-azolylbutyl)homopiperazinyl)- and 2-(4-(4-azolylbutyl)homopiperazinyl)methylbenzimidazoles were synthesized, characterized and tested for in vitro and in vivo H1-antihistaminic activity. Structure-activity relationships impleid that the best antihistaminic activity required the simultaneous presence of a homopiperazinylbenzimidazole system (or a methylene linker between the benzimidazole and the piperazine rings) and an unsubstituted pyrazole ring. 1-(2-Ethoxyethyl)-2-4-[4-(pyrazol-l-yl)butyl]homopiperazin-l-yl}benzimidazole (17), at its dimaleate salt, has been chosen for further development.

  对新的 2-(4-(4-偶氮丁基)哌嗪基)-、2-(4-(4-偶氮丁基)哌嗪基甲基)-、2-(4-(4-偶氮丁基)均哌嗪基)- 和 2-(4-(4-偶氮丁基)均哌嗪基)甲基苯并咪唑进行了合成、表征和体内外 H1 抗组胺活性测试。结构-活性关系表明，最佳抗组胺活性需要同时存在均哌嗪基苯并咪唑体系（或苯并咪唑环和哌嗪环之间的亚甲基连接体）和未取代的吡唑环。我们选择了 1-（2-乙氧基乙基）-2-4-[4-（吡唑-1-基）丁基]均哌嗪-1-基}苯并咪唑（17）的二马来酸盐进行进一步开发。
• FLEXIBLE PIEZOELECTRIC AND FERROELECTRIC HALOIMIDAZOLE CRYSTALS
  申请人：NORTHWESTERN UNIVERSITY

  公开号：US20190127331A1

  公开（公告）日：2019-05-02

  Provided herein are substituted haloimidazole crystals, the substituted haloimidazole crystal comprising a substituted haloimidazole compound wherein the substituents are selected from the group consisting of hydrogen, an alkyl, and a halogen. The substituted haloimidazole crystals may further comprise second substituted haloimidazole. The substituted haloimidazole crystals may be piezoelectric, ferroelectric, flexible, or any combination thereof. Also provided herein are methods for preparing substituted haloimidazole crystals.

  本文提供了代替的卤代咪唑晶体，所述代替的卤代咪唑晶体包括一种代替的卤代咪唑化合物，其中取代基被选自氢、烷基和卤素的群体。代替的卤代咪唑晶体还可以包括第二代替的卤代咪唑。代替的卤代咪唑晶体可以是压电的、铁电的、柔性的或任何组合。本文还提供了制备代替卤代咪唑晶体的方法。

表征谱图